AMS 700 inflatable penile prosthesis with InhibiZone

Area of Science:

• Urology
• Biomaterials Science
• Infectious Disease

Background:

• Infection is the leading cause of failure for inflatable penile prostheses, surpassing mechanical malfunctions.
• Antibiotic coatings on medical devices have demonstrated efficacy in preventing bacterial colonization and biofilm formation.
• The AMS 700 series penile prosthesis, featuring InhibiZone (rifampin and minocycline), was developed to address implant-associated infections.

Purpose of the Study:

• To evaluate the effectiveness of the AMS 700 inflatable penile prosthesis with InhibiZone in reducing infection rates.
• To assess the impact of antibiotic impregnation on the rate of revision surgery due to infection in patients receiving penile implants.

Main Methods:

• Review of clinical studies and data on the AMS 700 penile prosthesis with InhibiZone.
• Analysis of infection rates and revision surgery rates in patients implanted with the antibiotic-coated device.
• Comparison of outcomes with historical data and devices without antibiotic coatings.

Main Results:

• Multiple studies confirm that the AMS 700 with InhibiZone significantly lowers infection rates in patients undergoing penile prosthesis implantation.
• The antibiotic-impregnated prosthesis has demonstrated a substantial reduction in the incidence of device-related infections.
• Clinical evidence supports the efficacy of this device in decreasing the need for revision surgeries caused by infection.

Conclusions:

• The AMS 700 inflatable penile prosthesis with InhibiZone is clinically proven to reduce infection rates, a critical factor in implant success.
• This antibiotic-coated device represents a significant advancement in managing erectile dysfunction, improving patient outcomes by minimizing infectious complications.
• The US FDA approval highlights the clinical evidence supporting the AMS 700 with InhibiZone as a key innovation for penile prosthesis surgery.